tradingkey.logo

Maravai LifeSciences Holdings Inc

MRVI
3.270USD
-0.030-0.91%
收盘 12/26, 16:00美东报价延迟15分钟
473.23M总市值
亏损市盈率 TTM

Maravai LifeSciences Holdings Inc

3.270
-0.030-0.91%

关于 Maravai LifeSciences Holdings Inc 公司

Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. It serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.

Maravai LifeSciences Holdings Inc简介

公司代码MRVI
公司名称Maravai LifeSciences Holdings Inc
上市日期Nov 20, 2020
CEOBrust (Bernd)
员工数量570
证券类型Ordinary Share
年结日Nov 20
公司地址10770 Wateridge Circle Suite 200
城市SAN DIEGO
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编92121
电话18585460004
网址https://www.maravai.com/
公司代码MRVI
上市日期Nov 20, 2020
CEOBrust (Bernd)

Maravai LifeSciences Holdings Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Bernd Brust
Mr. Bernd Brust
Chief Executive Officer, Director
Chief Executive Officer, Director
2.00M
--
Mr. Rajesh J. (Raj) Asarpota
Mr. Rajesh J. (Raj) Asarpota
Chief Financial Officer
Chief Financial Officer
500.00K
--
Mr. Kurt Oreshack
Mr. Kurt Oreshack
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
439.87K
+196.03%
Mr. Robert Andrew (Andy) Eckert
Mr. Robert Andrew (Andy) Eckert
Independent Chairman of the Board
Independent Chairman of the Board
365.89K
+172.22%
Ms. Christine Dolan
Ms. Christine Dolan
Executive Vice President, General Manager - Cygnus Technologies
Executive Vice President, General Manager - Cygnus Technologies
339.36K
+1.28%
Mr. Gregory T. (Greg) Lucier
Mr. Gregory T. (Greg) Lucier
Independent Director
Independent Director
175.77K
+131.98%
Ms. Susannah Gray
Ms. Susannah Gray
Independent Director
Independent Director
169.91K
+110.36%
Mr. Luke Joseph Marker
Mr. Luke Joseph Marker
Director
Director
138.06K
+182.23%
Dr. John A. Deford, Ph.D.
Dr. John A. Deford, Ph.D.
Independent Director
Independent Director
--
--
Mr. Sean L. Cunningham
Mr. Sean L. Cunningham
Director
Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Bernd Brust
Mr. Bernd Brust
Chief Executive Officer, Director
Chief Executive Officer, Director
2.00M
--
Mr. Rajesh J. (Raj) Asarpota
Mr. Rajesh J. (Raj) Asarpota
Chief Financial Officer
Chief Financial Officer
500.00K
--
Mr. Kurt Oreshack
Mr. Kurt Oreshack
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
439.87K
+196.03%
Mr. Robert Andrew (Andy) Eckert
Mr. Robert Andrew (Andy) Eckert
Independent Chairman of the Board
Independent Chairman of the Board
365.89K
+172.22%
Ms. Christine Dolan
Ms. Christine Dolan
Executive Vice President, General Manager - Cygnus Technologies
Executive Vice President, General Manager - Cygnus Technologies
339.36K
+1.28%
Mr. Gregory T. (Greg) Lucier
Mr. Gregory T. (Greg) Lucier
Independent Director
Independent Director
175.77K
+131.98%

收入明细

单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
由于公司未披露,未能获取相关数据
地区USD
名称
营收
占比
North America
30.64M
64.64%
Europe, the Middle East and Africa
8.39M
17.71%
Asia Pacific
8.16M
17.21%
Latin and Central America
327.00K
0.69%
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 11月17日 周一
更新时间: 11月17日 周一
持股股东
股东类型
持股股东
持股股东
占比
GTCR Golder Rauner, LLC
13.89%
12 West Capital Management, L.P.
8.63%
Hudson View Capital LLC
6.17%
Braidwell LP
5.76%
BlackRock Institutional Trust Company, N.A.
5.30%
其他
60.24%
持股股东
持股股东
占比
GTCR Golder Rauner, LLC
13.89%
12 West Capital Management, L.P.
8.63%
Hudson View Capital LLC
6.17%
Braidwell LP
5.76%
BlackRock Institutional Trust Company, N.A.
5.30%
其他
60.24%
股东类型
持股股东
占比
Investment Advisor
29.58%
Hedge Fund
25.00%
Investment Advisor/Hedge Fund
17.45%
Private Equity
13.89%
Individual Investor
6.63%
Corporation
6.17%
Research Firm
4.39%
Pension Fund
0.20%
Bank and Trust
0.14%

机构持股

更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
518
128.65M
88.93%
-44.43M
2025Q2
560
144.27M
100.21%
-25.80M
2025Q1
589
133.65M
92.84%
-44.45M
2024Q4
580
144.56M
101.93%
-33.57M
2024Q3
603
148.21M
104.79%
-33.05M
2024Q2
611
152.09M
114.44%
-19.50M
2024Q1
609
139.87M
105.40%
-26.88M
2023Q4
621
137.21M
103.78%
-26.31M
2023Q3
641
137.53M
104.23%
-17.92M
2023Q2
646
129.68M
98.32%
-22.48M
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
GTCR Golder Rauner, LLC
20.15M
13.93%
--
--
Jun 30, 2025
12 West Capital Management, L.P.
12.52M
8.65%
--
--
Jun 30, 2025
Hudson View Capital LLC
6.87M
4.75%
+6.87M
--
May 21, 2025
Braidwell LP
8.35M
5.77%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.41M
5.81%
+52.73K
+0.63%
Jun 30, 2025
The Vanguard Group, Inc.
9.38M
6.48%
-2.26M
-19.38%
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
2.64M
1.83%
+2.64M
--
Jun 30, 2025
Mackenzie Investments
6.07M
4.2%
-44.32K
-0.72%
Jun 30, 2025
Renaissance Technologies LLC
4.19M
2.89%
+75.50K
+1.84%
Jun 30, 2025
Mirabella Financial Services LLP
3.75M
2.59%
+10.05K
+0.27%
Jun 30, 2025
查看更多

持股ETF

更新时间: 12月2日 周二
更新时间: 12月2日 周二
机构名称
占比
Global X Genomics & Biotechnology ETF
0.41%
Invesco Nasdaq Biotechnology ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.04%
iShares Biotechnology ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
Schwab U.S. Small-Cap ETF
0.01%
iShares Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares Hedge Replication ETF
0.01%
查看更多
Global X Genomics & Biotechnology ETF
占比0.41%
Invesco Nasdaq Biotechnology ETF
占比0.05%
ProShares Ultra Nasdaq Biotechnology
占比0.04%
iShares Biotechnology ETF
占比0.03%
Invesco RAFI US 1500 Small-Mid ETF
占比0.03%
iShares Russell 2000 Value ETF
占比0.02%
Schwab U.S. Small-Cap ETF
占比0.01%
iShares Russell 2000 ETF
占比0.01%
Proshares Ultra Russell 2000
占比0.01%
ProShares Hedge Replication ETF
占比0.01%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据

常见问题

Maravai LifeSciences Holdings Inc的前五大股东是谁?

Maravai LifeSciences Holdings Inc 的前五大股东如下:
GTCR Golder Rauner, LLC持有股份:20.15M,占总股份比例:13.93%。
12 West Capital Management, L.P.持有股份:12.52M,占总股份比例:8.65%。
Hudson View Capital LLC持有股份:6.87M,占总股份比例:4.75%。
Braidwell LP持有股份:8.35M,占总股份比例:5.77%。
BlackRock Institutional Trust Company, N.A.持有股份:8.41M,占总股份比例:5.81%。

Maravai LifeSciences Holdings Inc的前三大股东类型是什么?

Maravai LifeSciences Holdings Inc 的前三大股东类型分别是:
GTCR Golder Rauner, LLC
12 West Capital Management, L.P.
Hudson View Capital LLC

有多少机构持有Maravai LifeSciences Holdings Inc(MRVI)的股份?

截至2025Q3,共有518家机构持有Maravai LifeSciences Holdings Inc的股份,合计持有的股份价值约为128.65M,占公司总股份的88.93%。与2025Q2相比,机构持股有所增加,增幅为-11.28%。

哪个业务部门对Maravai LifeSciences Holdings Inc的收入贡献最大?

在FY2025Q2,--业务部门对Maravai LifeSciences Holdings Inc的收入贡献最大,创收--,占总收入的--%。
KeyAI